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ABSTRACT
Objective: To determine, “Does treatment with amantadine improve the rate of cognitive
function in patients with Traumatic Brain Injury?”
Study Design: Review of three English language randomized controlled trials from 1999-2012
Data Sources: Three randomized, placebo-controlled, double blind crossover trials comparing
amantadine to placebo were found using Pub-Med and Cochrane Databases.
Outcomes Measured: The trials measured the effects of amantadine on command-following,
object recognition, functional object use, intelligible verbalization, reliable yes-or-no
communication, sustained attention, orientation, attention, memory, executive flexibility, and
behavior and used the following assessment tools: Neurobehavioral Rating Scale and DRS
(Disability Rating Scale).
Results: Two studies demonstrated an improvement in eye opening, verbalization, motor
response, cognitive understanding of feeding, dressing, and grooming; degree of assistance and
supervision required; and employability at higher rates than the placebo. One study did not
indicate an increase of rate in improvement of cognitive function when comparing amantadine to
placebo.
Conclusion: Based on two of the trials, treatment with amantadine does increase the rate of
improvement of cognitive function in patients suffering from Traumatic Brain Injury. One trial
did not show an increase in rate of improvement, but small sample size discounted its validity.
Key Words: Traumatic Brain Injury, Cognitive Function, Amantadine
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Introduction
Each year, severe traumatic brain injury contributes to a significant number of deaths and
cases of permanent disability, as well as economic and familial consequences.2 TBI is the most
common cause of death and disability in persons aged 15-30 and accounts for approximately
one-third of all injury related deaths in the United States.1,2 The direct and indirect costs of TBI
in the US have been estimated to be $48.3 billion annually.5 Survival costs account for $31.7
billion and fatal brain injuries cost another $16.6 billion.5
Physical effects of traumatic brain injury can range from minimal symptoms like
headaches, nausea, and dizziness to more severe consequences, such as decreased consciousness
and cognitive function, vegetative states, and death.2,3,4 The severity of internal or external brain
damage correlates to the amount of cognitive dysfunction. The higher the severity of trauma to
the skull/brain, the more severe the dysfunction will be, thereafter. High-speed motor vehicle
collisions cause 50% of traumatic brain injuries in the United States and tend to have the most
detrimental effects.3
For severe TBIs, it is not known for sure how long a particular patient will take to regain
lost cognitive function or to what degree that patient will heal. A majority of healing occurs
spontaneously and shortly after injury.4 There are off-label neuropharmicological therapies that
attempt to increase consciousness and arrousability by tampering with dopaminergic and
noradrenergic receptors, but the exact mechanism by which these medications work is not fully
understood and effects are generally temporary.3
There is no current cure for Traumatic Brain Injury.2,3,4 Methods of pharmacological
treatment are aimed at control of systemic physiological effects of TBI.3 Diuretics are used to
decrease the amount of third-spacing as well as intracranial pressures. Beta-blockers, ACEi and
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ARBS are used to regulate blood pressure. Medications to prevent seizures and control pain are
also utilized, but stabilizing a TBI patient with these pharmacological agents does not improve
the amount of cognitive damage initially sustained. Currently the main methods of treatment of
long-term cognitive damage are physical, speech, and occupational therapies.3
Typically in the case of severe traumatic brain injury, such as those sustained in a motor
vehicle collision, the mechanism is diffuse axonal injury (DAI).3 DAI involves a widespread
damage to axons in the brain and is highly associated with a reduction of dopamine availability.3
Amantadine is a medication that causes increased release of dopamine from neurons in the brain
and delay of cellular uptake.3 It is known for its use as an antiparkinsonian agent and as an
antiviral in treatment of influenza.3 Currently it is a topic for research in the area of traumatic
brain injury, and is the focus of this systematic review.
Objective
The objective of this selective EBM review is to determine “Does treatment with
Amantadine increase the rate of improvement of cognitive function in patients suffering TBI?”
Previous studies have showed the benefits of using dopamine agonists in treatment of cognitive
dysfunction; therefore, it is suggested that amantadine will have a positive impact on the rate of
cognitive recovery in patients with TBI.
Methods
An online search was done to locate randomized control trials evaluating the use of
amantadine in patients suffering TBI. Articles used included male and female patients above the
age of 16 with TBI and excluded those with previous chronic disease or cognitive disability. 50
– 200 mg BID of Amantadine was compared with placebo in its affects on cognitive dysfunction
and DRS and Neurobehavioral Rating Scale were used to evaluate that dysfunction.
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Key words used in the search engine Pub-Med included were “cognitive function”,
“amantadine”, and “Traumatic Brain Injury”. All articles used were English language
randomized, double-blind, controlled cross-over studies from 1999 to 2012. The articles were
selected based on the importance of the outcomes to the patient.
Outcomes Measured
The outcomes evaluated were POEMS (Patient Oriented Evidence that Matters). For
example, DRS and Neurobehavioral Rating scores were measured by rating improvements in
several types of cognitive functioning. The DRS (Disability Rating Scale) measured consistent
command-following, object recognition, functional object use, intelligible verbalization, reliable
yes-or-no communication, and sustained attention scores. Scores were measured as a function of
time, where disability was scored using a number scale; 7-13 being moderate-severe-to-severe,
14-21 severe-to-extremely-severe, and 22-29 vegetative-state-to-extreme-vegetative-state. The
Neurobehavioral Rating scale involved tests in orientation, attention, memory, executive
flexibility, and behavior as a function of time. Functioning tests included consistent commandfollowing, reliable yes-or-no communication, and sustained attention.
Table 1. Demographics of included studies
#
Inclusion
Study
Type
Age
Pts
Criteria
Giacano
(2012)

DoubleBlind,
RCT,
Placebocontrolled

Meythaler Double(2002)
Blind,
RCT,
Placebo-

184 1665

35

1675

Patients who
sustained a
nonpenetrating
traumatic brain
injury who are
currently in a
vegetative state
or a minimally
conscious state
Patients with a
GCS of less than
11, loss of
consciousness

Exclusion
Criteria

W.D Interventions

Any patient
with a CNS
disability that
predated the
TBI

3

Amantadine

Patients with
penetrating
TBI, prior
experimental

5

Amantadine
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Schneider
(1999)

DoubleBlind,
RCT,
PlaceboControlled

10

1855

immediately
after a MVC,
posttraumatic
amnesia for at
least 1 week
Diagnosis of
closed head
injury, deficits
in attention and
concentration

6

drug use,
history of
cardiac
disease
Pts with hx of
cardiac
disease,
pregnant,
psych history

8

Amantadine

Results
Three randomized controlled trials are presented in this review, using cognitive grading
scales to track progress over time, with study participants being clinically diagnosed with
Traumatic Brain Injury. One trial was analyzed with intention to treat while the others as
change in mean cognitive scores from baseline.
In the Galiano et al study, participants were given BID doses of 100 mg Amantadine for
14 days, 150 mg at week three, and 200 mg at week four.2 A visually matched BID dose placebo
was given to the control group.2
181 patients completed the trial. At the end of the 4-week treatment interval, both the
amantadine and control group had significant improvements in DRS scores, but the amantadine
group had a faster rate of recovery. Also, more patients in the amantadine group had positive
DRS score outcomes and greater percentage of recovery at the end of the trial, as shown in Table
1.2
Table 2. Distribution of DRS scores after 4-week trial2
Method Used
Amantadine

Percentage of modsevere-to-severe
disability (95% CI)
25.6

Percentage of
severe-toextremely-severe
(95% CI)
55.8

Percentage of
vegetative state to
extreme vegetative
(95% CI)
18.6
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16.8

51.6

7

31.6

To analyze treatment effects, absolute benefit increase (ABI), relative benefit increase
(RBI), and numbers needed to treat (NNT) values were used, shown below in Table 3. RBI and
ABI were calculated as 0.52% and 0.09%, respectively, while the number of patients needed to
treat was 12.2
Table 3. Treatment effects of randomized, placebo-controlled, double-blind crossover trial
EER- CER
EER – CER
1/ABI
CER
EER
CER
(ABI)
(NNT)
(RBI)
0.168

0.256

0.523

0.09

12

The Methayler et al trial included a study sample of 35 patients with diagnosed Traumatic
Brain Injury. Amantadine 200 mg QD was given to group one for 6 weeks, while group two was
given a visually matched placebo. For weeks 6-12 group one was given placebo and group two
was given amantadine.
All patients’ baseline DRS scores were taken and averaged as a whole in their respective
groups. After 6-week treatment with either placebo or amantadine, mean DRS scores were again
taken, producing a new average for both groups. New means were analyzed, using statistical
procedures Wilcoxon signed-rank test and Mann-Whitney U test, shown below in Table 4. After
the initial 6 weeks, group one showed an improvement in DRS scores of 9.8 point (15.5 ± SD 4.5
to 5.7 ± SD 4.2) improvement in DRS score, while showing a 0.15 point (5.7 ± SD 4.12 to 5.5 ±
SD 4.6) during the second 6 weeks.3
Group two had a 9.4 point (21.7 ± 7.8 to 12.3 ± 9.9) improvement in DRS score and a 3.8
point (12.3 ± 9.9 to 8.5 ± 9.0) improvement during weeks 6-12, while taking amantadine. The
Mann-Whitney U test showed a statistically different DRS point score at week zero, as
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evidenced by P score of .0455 shown below, but there was still a statistically significant amount
of change in favor of the amantadine group 2 at weeks 6 thru 12 (P=.2269).3
Table 4. Wilcoxon Matched-Pair, Signed-Rank test results + Mann-Whitney U test.3
P-Values (Weeks 0-6)

P-Values (Weeks 6-12)

Group 1

0.0022

>0.05

Group 2

0.0006

0.0099

Mann-Whitney U test

0.045

0.2269

DRS Cognitive Function
Assessment

In the review by Schneider et al, 10 participants diagnosed with TBI were separated into
two groups. Group one was started on 50 mg BID of amantadine and dose was increased every 3
days to 150 mg. After 2 weeks, patients were subjected to 2 weeks withdrawal, followed by 2
weeks placebo. Group two was given placebo for two weeks, followed by two weeks
withdrawal, and then amantadine 50 mg BID with dose increased every 3 days up to 150 mg.4
Although only 2 subjects followed the trial to completion, the results were reported and
analyzed. Information was examined using repeated measures analysis of variance, which
looked at test score results of five cognitive function variables: orientation, attention, memory,
executive flexibility, behavior, and composite variable. Scores in these areas were recorded over
time and repeatedly compared to baseline scores. This allowed researchers to compare results
before and after testing. Time by group interactions tests compared those scores over time with
scores of the other group, indicating whether or not changes over time were different from
amantadine group than placebo. Results are shown below in Table 5.4
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Table 5. Results of repeated measures of variance for effects of time4
Orientation

Attention

Memory

Executive
flexibility

Behavior

Composite
variable

Time

p = 0.032

p = 0.047

p = 0.012

p = 0.001

p = 0.017

p = 0.003

Time by
group

p = 0.849

p = 0.548

p = 0.425

p = 0.261

p = 0.852

p = 0.722

Group

p = 0.062

p = 0.325

p = 0.341

p = 0.732

p = 0.737

p = 0.405

All scores improved over time between both groups one and two and there was no
difference in rates of improvement. This suggests that although cognitive function improved
over time, the improvement was equal with and without amantadine.4
Discussion
The Methayler and Giacano randomized control trials showed benefit in the use of
amantadine following Traumatic Brain Injury. These two trials showed an increased rate in
cognitive function improvement, as measured by DRS, when compared to placebo. The
Schneider trial did not show a difference between the use of amantadine and placebo.
The Schneider trial offered conflicting information. Although there were only two
subjects who followed the trial to completion, initially only 10 subjects signed on, which is
already too small a number to find significant effects. Also, the rate of spontaneous recovery
following a TBI is known to be high, which could have masked the positive effects of
amantadine.4
The Methayler and Giacino studies both showed results consistent with acceleration of
cognitive recovery in patients with acute losses of cognitive function following TBI. Neither
study demonstrated a benefit with early treatment compared to later and both seem to showed an
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eventual “leveling-off” of DRS scores between amantadine and placebo groups. However, both
studies did demonstrate that patients improved more rapidly while on amantadine and
improvement was sustained after follow-up.2,3
Conclusion
Based on two of the trials addressed in this review, treatment with amantadine increases
the rate of cognitive function improvement in patients with traumatic brain injury. One study
showed no benefit in the use of amantadine for TBI, but a small sample size hindered its validity.
Overall, it can be inferred that amantadine does have a positive impact on the rate of cognitive
recovery following TBI.
Although the Schneider study did not agree with the Methayler or Giacino, it provides an
example of the importance of a large sample size. It also demonstrates the difficulty in finding
subjects for studies involving TBI. Since decreased consciousness and cognitive function are
central side effects of severe TBI, healthcare decision making for victims is often left in the
hands of family members. One can expect that some family members would be hesitant to
subject their loved one to a pharmaceutical study of any kind during such a critical time.
Usage of amantadine in the realm of traumatic brain injury will likely continue to be
explored and studied. With proper education regarding its potential benefits and decreased side
effects, more subjects for research will come. This review provides significant patient-oriented
evidence as well as incentive for further investigation.

Voit – Amantadine & Cognitive Function 11
REFERENCES
1. Faul M, Xu L, Wald MM, Coronado VG. Traumatic brain injury in the United States:
emergency department visits, hospitalizations, and deaths. Atlanta (GA): Centers for Disease
Control and Prevention, National Center for Injury Prevention and Control; 2010.
2. Giacino JT, Whyte J, Bagiella E, et al. Placebo-controlled trial of amantadine for severe
traumatic brain injury. N Engl J Med. 2012;366(9):819-826. doi: 10.1056/NEJMoa1102609;
10.1056/NEJMoa1102609.
3. Meythaler JM, Brunner RC, Johnson A, Novack TA. Amantadine to improve neurorecovery
in traumatic brain injury-associated diffuse axonal injury: A pilot double-blind randomized
trial. J Head Trauma Rehabil. 2002;17(4):300-313.
4. Schneider WN, Drew-Cates J, Wong TM, Dombovy ML. Cognitive and behavioural efficacy
of amantadine in acute traumatic brain injury: An initial double-blind placebo-controlled
study. Brain Inj. 1999;13(11):863-872.
5. Selected Traumatic Brain Injury Statistics. Family Caregiver Alliance website.
http://www.caregiver.org/caregiver/jsp/content_node.jsp?nodeid=441 Accessed September
27, 2013

